Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Part of paid clinical trials in Dothan, Alabama.
- Sponsor
- Regeneron Pharmaceuticals
- Study ID
- NCT07175428
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Atrial Fibrillation (AF)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- REGN7508 — DRUGAdministered per the protocol
- REGN9933 — DRUGAdministered per the protocol
- Apixaban — DRUGAdministered per the protocol
Study Details
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots. The study is looking at several other research questions, including: * What side effects may happen from taking REGN7508 or REGN9933 * How well do the study drugs reduce the risk of having a stroke * How much of REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)
Key Dates
- Start date
- Oct 20, 2025
- Status verified
- May 2026
- Primary completion
- Feb 9, 2027
- Completion
- Apr 21, 2027
Study Design
- Enrollment
- 1,200 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Experimental: REGN7508
- Experimental: REGN9933
- Active Comparator: Apixaban
Primary Outcome Measure
Incidence of any bleeding [ Time Frame: 12 weeks ]
Central Contacts
- Clinical Trials Administrator844-734-6643
Locations (35)
Find similar trials in Dothan, AL
Related Studies
- Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)PHASE3 · Recruiting · Anthos Therapeutics, Inc. · Birmingham, Alabama
- Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial FibrillationEARLY_PHASE1 · Recruiting · China National Center for Cardiovascular Diseases · Boston, Massachusetts
- Full-Avoidance vs. Permissive/Regulated Drinking & Outcomes On FibrillationRecruiting · University of California, San Francisco · San Francisco, California
- COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG WearableEnrolling By Invitation · Peerbridge Health, Inc · Melbourne, Florida